Evidence map›Paper›PMID 33474647›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2021

Developmental delay with hypotrophy associated with homozygous functionally relevant REV3L variant.

Agnieszka Halas, Jolanta Fijak-Moskal, Renata Kuberska, Victor Murcia Pienkowski, Aneta Kaniak-Golik, Agnieszka Pollak, Jarosław Poznanski, Malgorzata Rydzanicz, Mirosław Bik-Multanowski, Ewa Sledziewska-Gojska and 1 more

Open access · greenAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. The Etiology of Moebius Syndrome-Making the Case for Animal Models.International journal of molecular sciences · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Agnieszka HalasInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106, Warsaw, Poland.
Jolanta Fijak-MoskalDepartment of Medical Genetics, Jagiellonian University Medical College, 30-663, Krakow, Poland.
Renata KuberskaInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106, Warsaw, Poland.
Victor Murcia PienkowskiDepartment of Medical Genetics, Medical University of Warsaw, 02-106, Warsaw, Poland.
Aneta Kaniak-GolikInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106, Warsaw, Poland.
Agnieszka PollakDepartment of Medical Genetics, Medical University of Warsaw, 02-106, Warsaw, Poland.
Jarosław PoznanskiInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106, Warsaw, Poland.
Malgorzata RydzaniczDepartment of Medical Genetics, Medical University of Warsaw, 02-106, Warsaw, Poland.
Mirosław Bik-MultanowskiDepartment of Medical Genetics, Jagiellonian University Medical College, 30-663, Krakow, Poland.
Ewa Sledziewska-Gojska *Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106, Warsaw, Poland. esg@IBB.waw.pl.
Rafał Płoski *Department of Medical Genetics, Medical University of Warsaw, 02-106, Warsaw, Poland. rploski@wp.pl.ORCID 0000-0001-6286-5526
Institute of Biochemistry and Biophysics, Polish Academy of Sciences · PLMedical University of Warsaw · PLJagiellonian University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

REV3L encodes a catalytic subunit of DNA polymerase zeta (Pol zeta) which is essential for the tolerance of DNA damage by inducing translesion synthesis (TLS). So far, the only Mendelian disease associated with REV3L was Moebius syndrome (3 patients with dominant REV3L mutations causing monoallelic loss-of-function were reported). We describe a homozygous ultra-rare REV3L variant (T2753R) identified with whole exome sequencing in a child without Moebius syndrome but with developmental delay, hypotrophy, and dysmorphic features who was born to healthy parents (heterozygous carriers of the variant). The variant affects the amino acid adjacent to functionally important KKRY motif. By introducing an equivalent mutation (S1192R) into the REV3 gene in yeasts, we showed that, whereas it retained residual function, it caused clear dysfunction of TLS in the nucleus and instability of mitochondrial genetic information. In particular, the mutation increased UV sensitivity measured by cell survival, decreased both the spontaneous (P < 0.005) and UV-induced (P < 0.0001) mutagenesis rates of nuclear DNA and increased the UV-induced mutagenesis rates of mitochondrial DNA (P < 0.0005). We propose that our proband is the first reported case of a REV3L associated disease different from Moebius syndrome both in terms of clinical manifestations and inheritance (autosomal recessive rather than dominant). KEY MESSAGES: First description of a human recessive disorder associated with a REV3L variant. A study in yeast showed that the variant affected the enzymatic function of the protein. In particular, it caused increased UV sensitivity and abnormal mutagenesis rates.

Indexed as

Mutation, MissensePoint MutationAldose-Ketose IsomerasesCatalytic DomainChild, PreschoolDevelopmental DisabilitiesDNADNA-Binding ProteinsDNA-Directed DNA PolymeraseDNA, FungalDNA, MitochondrialExome SequencingFemaleHomozygoteHumansMaleAldose-Ketose IsomerasesDNADNA-Binding ProteinsDNA-Directed DNA PolymeraseDNA, FungalDNA, MitochondrialREV3L protein, humanREV3 protein, S cerevisiaeSaccharomyces cerevisiae ProteinsTRP1 protein, S cerevisiaeDNA polymerase zetaMitochondrial DNA stabilityMutagenesisREV3LUV sensitivity

Identifiers

PMID33474647
OpenAlexW3125088155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.